Abstract
Lung cancer treatment has taken a paradigm shift with advent of molecular therapy. This study evaluates lung adenocarcinoma cases for molecular markers EGFR, ALK, ROS-1 and MET testing. A total of 4485 cases of lung carcinomas were enrolled from the period of October 2010 to June 2016 in a North Indian tertiary Cancer Centre. Amongst these 815 cases after workup were found to be stage IV adenocarcinoma. Molecular mutation analysis was done for EGFR, ALK, ROS1 and C-MET amplification in 778, 522, 51 and 50 cases respectively. EGFR mutation testing was done using Qiagen Therascreen EGFR kit and Sanger sequencing, ALK testing was done using ALK IHC (clone anti-ALK D5F3), ROS1 gene rearrangement and MET gene amplification using Zytolight DNA FISH probes. The incidence of these biomarkers and its association with the age, sex, smoking history, histological subtype, site of biopsy, treatment history and survival outcome would be analyzed. Late breaking. Will complete information later. Late breaking abstract. Will be completed later.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
